BioCryst Pharmaceuticals Inc (BCRX)
7.485
+0.18
(+2.53%)
USD |
NASDAQ |
Nov 21, 16:00
7.485
0.00 (0.00%)
After-Hours: 20:00
BioCryst Pharmaceuticals Net Income (Quarterly): -14.03M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -14.03M |
| June 30, 2024 | -12.67M |
| March 31, 2024 | -35.38M |
| December 31, 2023 | -61.73M |
| September 30, 2023 | -36.15M |
| June 30, 2023 | -75.33M |
| March 31, 2023 | -53.33M |
| December 31, 2022 | -71.54M |
| September 30, 2022 | -42.52M |
| June 30, 2022 | -58.86M |
| March 31, 2022 | -74.20M |
| December 31, 2021 | -17.78M |
| September 30, 2021 | -58.80M |
| June 30, 2021 | -43.20M |
| March 31, 2021 | -64.28M |
| December 31, 2020 | -60.49M |
| September 30, 2020 | -46.12M |
| June 30, 2020 | -38.61M |
| March 31, 2020 | -37.60M |
| December 31, 2019 | -2.622M |
| September 30, 2019 | -37.59M |
| June 30, 2019 | -37.63M |
| March 31, 2019 | -31.05M |
| December 31, 2018 | -27.43M |
| September 30, 2018 | -29.60M |
| Date | Value |
|---|---|
| June 30, 2018 | -18.45M |
| March 31, 2018 | -25.78M |
| December 31, 2017 | -19.54M |
| September 30, 2017 | -15.13M |
| June 30, 2017 | -16.89M |
| March 31, 2017 | -14.22M |
| December 31, 2016 | -4.503M |
| September 30, 2016 | -11.53M |
| June 30, 2016 | -16.28M |
| March 31, 2016 | -22.83M |
| December 31, 2015 | -18.14M |
| September 30, 2015 | -14.62M |
| June 30, 2015 | 4.901M |
| March 31, 2015 | -15.16M |
| December 31, 2014 | -11.67M |
| September 30, 2014 | -8.731M |
| June 30, 2014 | -14.65M |
| March 31, 2014 | -10.14M |
| December 31, 2013 | -5.429M |
| September 30, 2013 | -8.001M |
| June 30, 2013 | -12.17M |
| March 31, 2013 | -4.506M |
| December 31, 2012 | -11.05M |
| September 30, 2012 | -9.70M |
| June 30, 2012 | -12.28M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-75.33M
Minimum
Jun 2023
-2.622M
Maximum
Dec 2019
-45.26M
Average
-44.66M
Median
Net Income (Quarterly) Benchmarks
| AIM ImmunoTech Inc | -3.70M |
| Perspective Therapeutics Inc | -15.12M |
| Protalix BioTherapeutics Inc | 3.236M |
| Electromed Inc | 1.474M |
| Armata Pharmaceuticals Inc | -5.481M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 117.08M |
| Total Expenses (Quarterly) | 109.39M |
| EPS Diluted (Quarterly) | -0.07 |
| Enterprise Value | 1.978B |
| Gross Profit Margin (Quarterly) | 97.24% |
| Profit Margin (Quarterly) | -11.99% |
| Earnings Yield | -8.15% |
| Normalized Earnings Yield | -8.124 |